Home / Deep Research / Neurofibroma

Neurofibroma

1. Disease Information

2026-06-30
Falcon MONDO:0016755 Model: Edison Scientific Literature 62 citations

1. Disease Information

Overview

Neurofibroma is a benign peripheral nerve sheath tumor (PNST) composed predominantly of Schwann cells, fibroblasts, perineurial-like cells, mast cells, and extracellular matrix, arising in the context of neurofibromatosis type 1 (NF1), the most common tumor predisposition syndrome (sur2022neurofibromatosisinchildren pages 1-2, mo2022neurofibrominandsuppression pages 1-3). NF1 is an autosomal dominant neurocutaneous disorder caused by germline pathogenic variants in the NF1 gene on chromosome 17q11.2, which encodes neurofibromin, a tumor suppressor protein functioning as a negative regulator of RAS signaling (kitsera2026moleculargeneticsand pages 2-3, anastasaki2022rasandbeyond pages 2-3). Neurofibromas represent the hallmark neoplastic manifestation of NF1 and include several histopathologically and clinically distinct subtypes: cutaneous neurofibromas (cNF), plexiform neurofibromas (pNF), subcutaneous neurofibromas, and diffuse neurofibromas (sur2022neurofibromatosisinchildren pages 2-4, yu2025emergingmechanismand pages 2-4, imataka2025neurofibromatosistype1 pages 4-5).

Key Identifiers

The following table summarizes key disease identifiers and characteristics:

Table (click to expand)
Disease name MONDO ID OMIM Orphanet ICD-10 / ICD-11 MeSH Common synonyms Inheritance pattern Prevalence Incidence Causal gene Chromosome location Protein product Key pathway
Neurofibroma MONDO:0016755 Not established for neurofibroma as a standalone entity; commonly contextualized within NF1 Not established for isolated neurofibroma in the gathered evidence ICD-10: D36.1 (benign neoplasm of peripheral nerves and autonomic nervous system); ICD-11: peripheral nerve sheath benign neoplasm category, exact code not established here MeSH term used for neurofibroma exists, but identifier not established in gathered evidence Peripheral nerve sheath tumor; cutaneous neurofibroma; dermal neurofibroma; plexiform neurofibroma; diffuse neurofibroma Usually occurs in the setting of NF1, which is autosomal dominant with many de novo cases; tumor formation follows a somatic second-hit mechanism in NF1-deficient Schwann lineage cells (sur2022neurofibromatosisinchildren pages 1-2, anastasaki2022rasandbeyond pages 2-3) NF1 pooled prevalence: 1 in 3,164 (95% CI 1 in 2,132-1 in 4,712); nearly all adults with NF1 develop cutaneous neurofibromas, and 30-50% develop plexiform neurofibromas (lee2023incidenceandprevalence pages 1-2, yu2025emergingmechanismand pages 2-4) NF1 pooled birth incidence: 1 in 2,662 (95% CI 1 in 1,968-1 in 3,601) (lee2023incidenceandprevalence pages 1-2, lee2023incidenceandprevalence pages 2-4) NF1 (neurofibromin 1) (kitsera2026moleculargeneticsand pages 2-3, mo2022neurofibrominandsuppression pages 1-3, anastasaki2022rasandbeyond pages 2-3) 17q11.2 (sur2022neurofibromatosisinchildren pages 1-2, hussain2024roleoflong pages 3-5) Neurofibromin, a ~2818 aa RAS-GTPase-activating tumor suppressor (kitsera2026moleculargeneticsand pages 2-3, mo2022neurofibrominandsuppression pages 1-3, anastasaki2022rasandbeyond pages 2-3) RAS/MAPK is the core dysregulated pathway; PI3K/AKT/mTOR is also activated downstream of NF1 loss (kitsera2026moleculargeneticsand pages 2-3, anastasaki2022rasandbeyond pages 2-3, lu2025neurofibromatosistype1 pages 2-4, OpenTargets Search: neurofibroma)

Table: This table summarizes key disease identifiers and high-yield characteristics for neurofibroma, emphasizing its close relationship to NF1-associated tumor biology. It is useful as a compact reference for ontology mapping, epidemiology, and molecular annotation.

  • MONDO ID: MONDO:0016755 (neurofibroma); MONDO:0018975 (neurofibromatosis type 1) (OpenTargets Search: neurofibroma)
  • OMIM: 162200 (Neurofibromatosis type 1)
  • ICD-10: D36.1 (Benign neoplasm of peripheral nerves and autonomic nervous system)
  • MeSH: D009455 (Neurofibroma)
  • Synonyms: Peripheral nerve sheath tumor, dermal neurofibroma, cutaneous neurofibroma, plexiform neurofibroma, von Recklinghausen disease-associated tumor

2. Etiology

Disease Causal Factors

Neurofibroma formation is driven by biallelic inactivation of the NF1 tumor suppressor gene following a classic Knudson two-hit model. Patients inherit one germline loss-of-function NF1 variant, and tumor initiation requires somatic loss of the remaining wild-type allele (loss of heterozygosity) in Schwann cell lineage progenitors (anastasaki2022rasandbeyond pages 2-3, lu2025neurofibromatosistype1 pages 2-4). Over 3,000 pathogenic NF1 variants have been documented, with more than 80% producing truncated, non-functional neurofibromin protein (lu2025neurofibromatosistype1 pages 2-4).

Genetic Risk Factors

Environmental Risk Factors

Radiation exposure is a recognized risk factor for malignant transformation (MPNST development) but is not considered a primary risk factor for benign neurofibroma formation (yao2023malignantperipheralnerve pages 2-4). Nerve injury may serve as a trigger for neurofibroma development, as demonstrated in animal models where sciatic nerve injury induced plexiform neurofibroma formation in NPcis mice (plante2024revisitingthenpcis pages 8-11, plante2024revisitingthenpcis pages 1-2).

3. Phenotypes

Clinical Manifestations of NF1 (with HPO term suggestions)

NF1 presents with multisystem manifestations that appear in an age-dependent manner (lalvani2024neurofibromatosistype1 pages 1-2, imataka2025neurofibromatosistype1 pages 2-4).

Cutaneous/Pigmentary Features: - Café-au-lait macules (CALMs): Present in ~85–95% of patients, appearing at birth or in early infancy as flat tan-brown hyperpigmented lesions (≥6 spots of ≥5 mm pre-pubertal or ≥15 mm post-pubertal). HPO: HP:0007565 (lalvani2024neurofibromatosistype1 pages 1-2, almuqbil2024epidemiologyandoutcomes pages 1-2, almuqbil2024epidemiologyandoutcomes pages 5-7) - Axillary/inguinal freckling (Crowe sign): Present in ~34.8% of patients, typically developing after age 5. HPO: HP:0001067 (almuqbil2024epidemiologyandoutcomes pages 5-7, peduto2023neurofibromatosistype1 pages 2-4)

Ophthalmologic Features: - Iris Lisch nodules: Melanocytic hamartomas present in ~36.4% of patients at a median age of 12 years. HPO: HP:0009737 (almuqbil2024epidemiologyandoutcomes pages 1-2, almuqbil2024epidemiologyandoutcomes pages 5-7) - Optic pathway gliomas: Found in ~36.4% in one multicenter study, typically diagnosed within the first decade of life. HPO: HP:0009734 (almuqbil2024epidemiologyandoutcomes pages 1-2)

Tumor Features: - Cutaneous neurofibromas: Skin tumors originating from cutaneous nerves, forming small rubbery nodules, affecting nearly all adult NF1 patients (>90%). HPO: HP:0001067 (yu2025emergingmechanismand pages 2-4, imataka2025neurofibromatosistype1 pages 4-5) - Plexiform neurofibromas: Complex tumors arising from large internal nerve plexuses, occurring in 30–60% of NF1 patients, often congenital, with ~15% risk of malignant transformation. HPO: HP:0009732 (yu2025emergingmechanismand pages 2-4, imataka2025neurofibromatosistype1 pages 4-5, busciglio2025thepathogenesisof pages 1-2)

Skeletal Abnormalities: - Dystrophic scoliosis (up to 30%), sphenoid wing dysplasia, tibial bowing, pseudoarthrosis. HPO: HP:0002650 (scoliosis), HP:0009736 (tibial pseudoarthrosis) (almuqbil2024epidemiologyandoutcomes pages 2-4, imataka2025neurofibromatosistype1 pages 2-4, imataka2025neurofibromatosistype1 pages 4-5)

Neurodevelopmental Features: - Cognitive deficits in approximately 70% of children, including learning disabilities (20.9%), communication disorders (33.8%), ADHD (4.9%), and intellectual disability (10.5%). HPO: HP:0001328 (specific learning disability), HP:0007018 (attention deficit) (almuqbil2024epidemiologyandoutcomes pages 1-2, almuqbil2024epidemiologyandoutcomes pages 5-7, sur2022neurofibromatosisinchildren pages 2-4)

Cardiovascular Features: - Cardiovascular abnormalities in 9.8%, including hypertension, congenital heart defects, and moyamoya syndrome (almuqbil2024epidemiologyandoutcomes pages 1-2, imataka2025neurofibromatosistype1 pages 4-5)

Quality of Life Impact

NF1 imposes significant quality-of-life burden. In a Chinese cohort study, pediatric NF1 patients had EQ-5D-Y utility scores of 0.880 ± 0.13 (VAS 75.38 ± 20.67), while adult patients had EQ-5D-5L utility scores of 0.843 ± 0.17 (VAS 72.32 ± 23.49). Over 50% of both groups reported problems with pain/discomfort, and 42.9–74.3% reported anxiety/depression (liang2024longtermdistressthroughout pages 1-2, liang2024longtermdistressthroughout pages 4-5). Pain occurs at young ages in 41% of patients requiring medication (sur2022neurofibromatosisinchildren pages 2-4).

4. Genetic/Molecular Information

Causal Gene: NF1 (Neurofibromin 1)

Pathogenic Variants

The NF1 gene is one of the largest in the human genome (~350 kb, 60 exons). Pathogenic variants span the entire gene, with over 3,000 documented mutations (lu2025neurofibromatosistype1 pages 2-4): - 90–95% are intragenic mutations (nonsense, frameshift, splice-site, missense) (peduto2023neurofibromatosistype1 pages 11-13) - 5–10% involve large deletions (17q11.2 microdeletion syndrome) associated with more severe phenotypes (hussain2024roleoflong pages 3-5, peduto2023neurofibromatosistype1 pages 11-13) - Mutation types include small/large insertions, deletions, chromosome rearrangements, stop mutations, splicing mutations, and amino acid substitutions (hussain2024roleoflong pages 3-5) - Functional consequence: Loss of function (>80% produce truncated protein) (lu2025neurofibromatosistype1 pages 2-4) - Somatic vs germline: Germline heterozygous mutation plus somatic second hit (biallelic inactivation) required for tumor formation (anastasaki2022rasandbeyond pages 2-3, lu2025neurofibromatosistype1 pages 2-4)

Genotype-Phenotype Correlations

Five key genotype-phenotype correlations have been identified (peduto2023neurofibromatosistype1 pages 11-13): - 17q11.2 microdeletion syndrome → more severe disease, earlier tumor onset - Missense variants at codons 844–848 (GRD) → severe phenotype with early tumor development (kitsera2026moleculargeneticsand pages 2-3) - Mutations in the CSRD domain → increased optic glioma risk (mo2022neurofibrominandsuppression pages 1-3, mo2022neurofibrominandsuppression pages 19-21) - p.Met992del → milder phenotype - p.Arg1809 substitutions → Noonan-like features (peduto2023neurofibromatosistype1 pages 11-13)

Malignant Transformation: Neurofibroma-to-MPNST Continuum

Malignant transformation follows a stepwise molecular cascade (busciglio2025thepathogenesisof pages 2-4, busciglio2025thepathogenesisof pages 1-2, busciglio2025thepathogenesisof pages 4-6): 1. Biallelic NF1 inactivation → constitutive RAS activation → benign neurofibroma 2. CDKN2A/B loss → ANNUBP (atypical neurofibromatous neoplasm of uncertain biological potential) 3. PRC2 disruption (SUZ12, EED, or EZH2 mutations/deletions) → H3K27me3 loss → high-grade MPNST

PRC2 inactivation occurs in 70–90% of MPNSTs and represents a defining molecular event, causing global epigenetic dysregulation and enhancer reprogramming (yao2023malignantperipheralnerve pages 2-4, busciglio2025thepathogenesisof pages 6-7). This leads to Schwann cell dedifferentiation, chromosomal instability, and immune-depleted microenvironments (busciglio2025thepathogenesisof pages 14-14, busciglio2025thepathogenesisof pages 10-12).

Epigenetic Information

DNA methylation profiling has emerged as a diagnostic tool for MPNST classification, with distinct methylation clusters corresponding to H3K27me3 status (busciglio2025thepathogenesisof pages 14-14, busciglio2025thepathogenesisof pages 10-12). LncRNAs including ANRIL and H19 show dysregulated expression in NF, influencing RAS/MAPK and JAK/STAT signaling pathways (hussain2024roleoflong pages 3-5).

5. Mechanism / Pathophysiology

Molecular Pathways

Loss of neurofibromin function leads to constitutive activation of multiple oncogenic signaling cascades (kitsera2026moleculargeneticsand pages 2-3, anastasaki2022rasandbeyond pages 2-3, lu2025neurofibromatosistype1 pages 2-4): - RAS/RAF/MEK/ERK (MAPK) pathway – primary proliferative signal; GO: GO:0000165 (MAPK cascade) - PI3K/AKT/mTOR pathway – survival and growth signaling - cAMP pathway – modulates differentiation and growth - RAS-Rac1 pathway – cytoskeletal regulation and cell migration

Neurofibromin normally converts active RAS-GTP to inactive RAS-GDP through its GAP-related domain (GRD), restraining downstream signaling (kitsera2026moleculargeneticsand pages 2-3, anastasaki2022rasandbeyond pages 2-3).

Cellular Processes

Tumor Microenvironment

Single-cell RNA sequencing has revealed the remarkable complexity of the neurofibroma tumor microenvironment (TME): - Schwann cells represent only ~4–10% of tumor cells in pNF, while immune and stromal cells comprise ~90% of human plexiform neurofibromas (kershner2022multiplenf1schwann pages 1-2, mclean2023singlecellrnasequencing pages 5-6) - Five distinct SC populations have been identified, including a novel SC progenitor-like (SCP-like) population (kershner2022multiplenf1schwann pages 1-2) - Macrophages (Iba1+CD11b+F4/80+) comprise ~30% of pNF cells with M2-polarized phenotype promoting immunosuppression (kershner2022multiplenf1schwann pages 1-2, mclean2023singlecellrnasequencing pages 11-13) - Fibroblasts form the collagen-rich matrix (CD34+), with six distinct populations identified, comprising over 70% of analyzed cells in porcine models (mclean2023singlecellrnasequencing pages 14-15, mclean2023singlecellrnasequencing pages 5-6) - Key cell-cell communication pathways: PROS1-AXL, FGF-FGFR, MIF-CD74, NF-κB, PTN-PTPRZ1, NRXN1-NLGN1, and collagen/laminin-integrin interactions (kershner2022multiplenf1schwann pages 1-2, swanson2025singlecellanalysisof pages 12-15) - Immunosuppressive features: IDO1+/PD-L1+ dendritic cells, M2 macrophages expressing IL-10 and ARG1, and Schwann cell-derived IL-34 promoting CSF1R-mediated M2 polarization (mclean2023singlecellrnasequencing pages 11-13, mclean2023singlecellrnasequencing pages 14-15)

Molecular Profiling

Single-nuclei RNA-sequencing integrated with spatial transcriptomics has identified distinct cellular subpopulations with remarkable inter-sample homogeneity, with the predominant fraction being fibroblast subtypes and NRXN1/NLGN1 receptor-ligand cross-talk predicted between fibroblasts and non-myelinated Schwann cells (swanson2025singlecellanalysisof pages 25-27, swanson2025singlecellanalysisof pages 12-15).

6. Anatomical Structures Affected

Organ Level

Tissue and Cell Level

Localization

7. Temporal Development

Onset

Progression

Prognosis

  • Benign neurofibromas: generally good prognosis; significant morbidity from pain, disfigurement, and neurological deficits
  • MPNST: poor prognosis with median survival of 11 months and 5-year survival rate as low as 6.8% for radiation-induced cases (yao2023malignantperipheralnerve pages 2-4)
  • High-grade PRC2/CDKN2A-deficient MPNSTs show significantly poorer survival (p = 0.0024) (busciglio2025thepathogenesisof pages 14-14)

8. Inheritance and Population

Epidemiology

A 2023 systematic review and meta-analysis of 12 studies reported (lee2023incidenceandprevalence pages 1-2, lee2023incidenceandprevalence pages 2-4, lee2023incidenceandprevalence pages 4-7): - Pooled NF1 prevalence: 1 in 3,164 (95% CI: 1 in 2,132–1 in 4,712) - Pooled NF1 birth incidence: 1 in 2,662 (95% CI: 1 in 1,968–1 in 3,601) - Screening studies identified higher prevalence (1 in 2,020) compared to medical record-based studies (1 in 4,329), suggesting significant under-recognition

Inheritance

9. Diagnostics

Clinical Criteria

The 2021 revised NIH diagnostic criteria for NF1 require ≥2 of the following (almuqbil2024epidemiologyandoutcomes pages 1-2, almuqbil2024epidemiologyandoutcomes pages 2-4, imataka2025neurofibromatosistype1 pages 2-4): - ≥6 CALMs (≥5 mm pre-pubertal, ≥15 mm post-pubertal) - ≥2 neurofibromas of any type or one plexiform neurofibroma - Axillary or inguinal freckling - Optic pathway glioma - ≥2 Lisch nodules or ≥2 choroidal abnormalities - Distinctive osseous lesion (sphenoid dysplasia, tibial bowing/pseudoarthrosis) - Heterozygous pathogenic NF1 variant - First-degree relative with NF1

Genetic Testing

Molecular analysis of the NF1 gene is fundamental for confirming diagnosis, especially in cases with atypical or incomplete clinical features, and for distinguishing from Legius syndrome (SPRED1 mutations) (peduto2023neurofibromatosistype1 pages 2-4). Sequencing approaches include next-generation sequencing panels, whole-exome, or whole-genome sequencing. Differential diagnosis includes Legius syndrome and other RASopathies (peduto2023neurofibromatosistype1 pages 2-4).

Imaging

Volumetric MRI is the standard for assessment of plexiform neurofibromas, used for both initial evaluation and monitoring treatment response (≥20% volume decrease defines partial response) (armstrong2023treatmentdecisionsand pages 2-4).

Biomarkers for Malignant Transformation

Circulating tumor DNA (ctDNA) analyses reveal distinctive copy number variations and methylation patterns that can detect malignant transformation (busciglio2025thepathogenesisof pages 1-2). H3K27me3 loss by immunohistochemistry is a highly sensitive marker for MPNST pathogenesis (yao2023malignantperipheralnerve pages 2-4). A 50-protein plasma panel has been identified that accurately distinguishes MPNST from premalignant tumors (from single-cell TME profiling-informed proteomic studies) (OpenTargets Search: neurofibroma).

10. Treatment

Current Treatment Landscape

The following table summarizes the therapeutic landscape for neurofibroma:

Table (click to expand)
Therapy Class / mechanism Main indication in neurofibroma Key clinical results FDA approval status Notable adverse effects / limitations
Selumetinib MEK1/2 inhibitor; suppresses RAF-MEK-ERK signaling downstream of NF1 loss Symptomatic, inoperable NF1-associated plexiform neurofibromas (PN), primarily pediatric Phase II: 68% confirmed partial response (34/50), median best tumor volume reduction 27.9%; Phase I/II long-term follow-up: 70% overall confirmed partial response with durable pain improvement; systematic review cites ~68-71% partial response (armstrong2023treatmentdecisionsand pages 2-4, souza2022clinicaltrialstargeting pages 5-6, souza2022clinicaltrialstargeting pages 9-10, imataka2025neurofibromatosistype1 pages 9-11) FDA approved in 2020 for pediatric patients with symptomatic, inoperable NF1-PN; also supported by approval-linked Open Targets evidence for MAP2K1/MAP2K2 (souza2022clinicaltrialstargeting pages 5-6, armstrong2023treatmentdecisionsand pages 2-4, OpenTargets Search: neurofibroma) Rash, vomiting, diarrhea, nausea, fatigue; grade 3 adverse events reported; cardiomyopathy and ocular toxicity require monitoring; prolonged therapy often needed because tumors may regrow after discontinuation (imataka2025neurofibromatosistype1 pages 12-13, imataka2025neurofibromatosistype1 pages 9-11)
Mirdametinib MEK inhibitor NF1-associated plexiform neurofibromas, including symptomatic/inoperable disease Partial response reported in 42-50% of patients, with improvements in pain and functioning in trial summaries/reviews (armstrong2023treatmentdecisionsand pages 6-7, souza2022clinicaltrialstargeting pages 6-7, souza2022clinicaltrialstargeting pages 9-10) FDA approved in 2024 for NF1 with symptomatic plexiform neurofibromas according to current treatment reviews and user-specified latest landscape; active studies ongoing (armstrong2023treatmentdecisionsand pages 6-7, souza2022clinicaltrialstargeting pages 6-7) Acneiform rash very common (~94.7% in one study summary), nausea, diarrhea; some patients required dose reductions; class toxicities similar to other MEK inhibitors (armstrong2023treatmentdecisionsand pages 6-7, souza2022clinicaltrialstargeting pages 6-7)
Trametinib MEK inhibitor Investigational treatment for NF1-associated plexiform neurofibromas, including pediatric populations Studied in children aged 1-17 years; efficacy signal noted in reviews, but no pivotal response rate as established as selumetinib in the cited evidence (armstrong2023treatmentdecisionsand pages 6-7, armstrong2023treatmentdecisionsand pages 2-4) Not FDA approved specifically for neurofibroma / NF1-PN in cited evidence Dermatologic and gastrointestinal class toxicities expected; long-term comparative efficacy remains uncertain (armstrong2023treatmentdecisionsand pages 6-7, imataka2025neurofibromatosistype1 pages 7-9)
Binimetinib MEK inhibitor Investigational therapy for NF1-associated plexiform neurofibromas Included in ongoing/previous clinical development programs for NF1-PN; no definitive response rate provided in the gathered evidence excerpt (souza2022clinicaltrialstargeting pages 5-6, armstrong2023treatmentdecisionsand pages 2-4) Not FDA approved specifically for neurofibroma / NF1-PN in cited evidence MEK inhibitor class toxicities likely, including rash and gastrointestinal events; evidence still emerging (souza2022clinicaltrialstargeting pages 5-6, imataka2025neurofibromatosistype1 pages 7-9)
Cabozantinib Multikinase tyrosine kinase inhibitor Unresectable, progressive, or symptomatic NF1-associated plexiform neurofibromas, especially adolescents/adults Partial response in 42% of patients; associated with pain reduction in reported studies/reviews (armstrong2023treatmentdecisionsand pages 6-7, souza2022clinicaltrialstargeting pages 6-7, souza2022clinicaltrialstargeting pages 9-10) Not FDA approved specifically for neurofibroma / NF1-PN in cited evidence Fatigue, gastrointestinal effects, hypothyroidism, dermatologic toxicities; used investigationally (armstrong2023treatmentdecisionsand pages 6-7)
NFX-179 topical gel Topical, metabolically labile MEK inhibitor Cutaneous neurofibromas (cNF) in NF1 Phase 2a: dose-dependent MEK inhibition with 47% reduction in p-ERK at 0.5%; 20% of treated cNFs had >=50% volume reduction vs 6% with vehicle after 28 days (OpenTargets Search: neurofibroma) Not FDA approved in cited evidence No local or systemic toxicities observed during short treatment period; systemic levels remained <1 ng/mL; durability still under study (OpenTargets Search: neurofibroma)
Imatinib Tyrosine kinase inhibitor Investigational treatment for plexiform neurofibromas Reported median tumor volume reduction of 26.5% in review summaries; explored before MEK inhibitors became standard (imataka2025neurofibromatosistype1 pages 7-9, imataka2025neurofibromatosistype1 pages 9-11) Not FDA approved specifically for neurofibroma / NF1-PN in cited evidence Limited efficacy compared with MEK inhibitors; off-target toxicities typical of TKIs; not current standard of care (imataka2025neurofibromatosistype1 pages 7-9)
Surgical resection / debulking Operative removal of tumor; potentially curative if complete excision feasible Symptomatic cutaneous or plexiform neurofibromas causing pain, neurologic deficit, disfigurement, airway compromise, or orthopedic complications Remains standard and only potentially curative local option, but many PN are unresectable; regrowth after surgery ranges ~20-68% depending on extent of resection (armstrong2023treatmentdecisionsand pages 6-7, armstrong2023treatmentdecisionsand pages 2-4) Standard clinical practice, not an FDA-regulated drug approval question Risks include bleeding, neurologic injury, incomplete resection, recurrence/regrowth, and anatomic inaccessibility (armstrong2023treatmentdecisionsand pages 6-7, armstrong2023treatmentdecisionsand pages 2-4, imataka2025neurofibromatosistype1 pages 7-9)
Gene therapy approaches Experimental gene restoration / editing strategies, including AAV-based NF1 restoration concepts Future disease-modifying therapy for NF1-associated neurofibromas and related tumors Preclinical/early translational only in gathered evidence; recent reviews highlight AAV-based gene therapy, gene-targeted approaches, and humanized/iPSC models to enable testing (lu2025neurofibromatosistype1 pages 2-4, mo2025humanizedneurofibromamodel pages 1-2) No FDA-approved gene therapy for neurofibroma in cited evidence Major limitations include delivery of the large NF1 gene, durability, tumor heterogeneity, and need for robust preclinical validation (lu2025neurofibromatosistype1 pages 2-4, mo2025humanizedneurofibromamodel pages 1-2)

Table: This table summarizes current and emerging treatments for neurofibroma, especially NF1-associated plexiform and cutaneous neurofibromas. It highlights mechanisms, indications, response rates, approval status, and key safety considerations to support knowledge base curation and comparative review.

Pharmacotherapy

Selumetinib (KOSELUGO®) is the first FDA-approved medical therapy for NF1-associated symptomatic, inoperable plexiform neurofibromas in pediatric patients aged ≥2 years. The pivotal SPRINT trial demonstrated a 68% confirmed partial response rate (34/50 patients) with median tumor volume reduction of 27.9% from baseline (armstrong2023treatmentdecisionsand pages 2-4). Long-term follow-up showed durable responses: 70% overall confirmed partial response with sustained pain improvement beyond 5 years of treatment (imataka2025neurofibromatosistype1 pages 9-11). Quality of life improved in 70% and pain reduced in 85% of patients with baseline pain (imataka2025neurofibromatosistype1 pages 9-11). The standard dosage is 25 mg/m² orally twice daily (imataka2025neurofibromatosistype1 pages 9-11).

Mirdametinib achieved 42–50% partial response rates with significant improvements in pain and functioning (armstrong2023treatmentdecisionsand pages 6-7, souza2022clinicaltrialstargeting pages 6-7).

NFX-179 Topical Gel, a metabolically labile MEK inhibitor for cutaneous neurofibromas, demonstrated dose-dependent MEK inhibition with a 47% decrease in p-ERK levels in a phase 2a trial, with excellent safety and no systemic toxicity (OpenTargets Search: neurofibroma).

Drug Targets (OpenTargets)

OpenTargets analysis identified the following validated drug targets for neurofibroma (MONDO:0016755) with association scores (OpenTargets Search: neurofibroma): - NF1 (neurofibromin 1) – score 0.699 - MAP2K1 (MEK1) – score 0.535 (clinical stage: APPROVAL) - MAP2K2 (MEK2) – score 0.532 (clinical stage: APPROVAL) - SPRED1 – score 0.480 (NF1-related pathway)

Surgical and Interventional

Surgical resection remains the only potentially curative option but is limited by incomplete resectability, with regrowth rates of 20–68% depending on extent of resection (armstrong2023treatmentdecisionsand pages 6-7, armstrong2023treatmentdecisionsand pages 2-4). MAXO term: MAXO:0000004 (surgical procedure).

Experimental Therapies and Clinical Trials

The following table summarizes active recruiting clinical trials:

Table (click to expand)
NCT number Brief study title Phase Intervention type Target enrollment Status
NCT05199376 Percutaneous cryotherapy for plexiform/unresectable neurofibromas in NF1 N/A Interventional; cryotherapy 30 Recruiting (OpenTargets Search: neurofibroma)
NCT07407803 TQ-B3234 capsules for symptomatic, non-surgical NF1-associated plexiform neurofibromas Phase 3 Interventional; small-molecule drug 177 Recruiting (OpenTargets Search: neurofibroma)
NCT07102394 IMLYGIC for cutaneous neurofibromas in adults with NF1 Phase 1 Interventional; oncolytic viral therapy 10 Recruiting (OpenTargets Search: neurofibroma)
NCT05331105 HL-085 in adults with NF1 and inoperable plexiform neurofibromas Phase 2 Interventional; small-molecule drug 70 Recruiting (OpenTargets Search: neurofibroma)
NCT06188741 Selumetinib for prevention of plexiform neurofibroma growth in NF1 Phase 2 Interventional; MEK inhibitor 200 Recruiting (OpenTargets Search: neurofibroma)
NCT06159166 Mirdametinib monotherapy in adults with NF1 and cutaneous neurofibromas Phase 1/2 Interventional; MEK inhibitor 24 Recruiting (OpenTargets Search: neurofibroma)
NCT06961565 PAS-004 in adults with NF1 and plexiform neurofibromas Phase 1 Interventional; investigational drug 56 Recruiting (OpenTargets Search: neurofibroma)
NCT06515860 NF1 Tumor Early Detection Study Observational Observational; early detection/biomarker study 1000 Recruiting (OpenTargets Search: neurofibroma)

Table: This table summarizes active/recruiting neurofibroma-related clinical studies identified in the search, highlighting trial phase, intervention type, enrollment, and current status. It is useful for quickly surveying the present translational and therapeutic pipeline in NF1-associated neurofibroma.

Emerging therapeutic strategies under investigation include AAV-based gene therapy for NF1 restoration, oncolytic herpes simplex virus (oHSV) therapy, CAR-T cell therapy targeting NF1-associated tumors, and combination strategies such as MEK + PAK inhibition for treatment-resistant tumors (lu2025neurofibromatosistype1 pages 2-4). Prolonged MEK inhibition induces compensatory phosphorylation of MEK and AKT, supporting the rationale for combination strategies (OpenTargets Search: neurofibroma).

11. Prevention

Primary Prevention

No primary prevention exists for NF1-associated neurofibromas given the genetic etiology. Genetic counseling is recommended for affected families. MAXO term: MAXO:0000127 (genetic counseling).

Secondary Prevention

  • Surveillance protocols: Regular clinical examinations, ophthalmologic assessments, developmental screening, and neuroimaging per age-appropriate guidelines (lalvani2024neurofibromatosistype1 pages 1-2, almuqbil2024epidemiologyandoutcomes pages 2-4)
  • Selumetinib for prevention: An active Phase 2 trial (NCT06188741) is investigating selumetinib for prevention of plexiform neurofibroma growth in NF1 (OpenTargets Search: neurofibroma)
  • Early detection: An NF1 Tumor Early Detection Study (NCT06515860) with 1,000 planned participants is currently recruiting (OpenTargets Search: neurofibroma)
  • Liquid biopsy: ctDNA-based approaches for early detection of malignant transformation are under development (busciglio2025thepathogenesisof pages 1-2)

Screening

Cascade genetic testing of first-degree relatives is recommended. Standardized genotyping enables early identification of high-risk genotypes (e.g., 17q11.2 microdeletion) for intensified surveillance (kitsera2026moleculargeneticsand pages 2-3, peduto2023neurofibromatosistype1 pages 11-13).

12. Model Organisms

Mouse Models

Multiple genetically engineered mouse models recapitulate aspects of human neurofibroma (plante2024revisitingthenpcis pages 8-11, plante2024revisitingthenpcis pages 1-2, plante2024revisitingthenpcis pages 11-12, plante2024revisitingthenpcis pages 2-4, mo2025humanizedneurofibromamodel pages 1-2): - Conditional Nf1 knockout models: Tissue-specific Cre recombinase (Krox20-Cre, P0-Cre, DhhCre, Hoxb7-Cre) combined with Nf1 flox mice generate para-spinal neurofibromas in 6–12 months - NPcis model: The most widely used MPNST model; develops MPNSTs in 3–6 months with 30% penetrance. Intentional sciatic nerve injury converts it into a plexiform neurofibroma model within 1–6 months with 50% penetrance (plante2024revisitingthenpcis pages 8-11, plante2024revisitingthenpcis pages 11-12, plante2024revisitingthenpcis pages 2-4) - Sox10-Cre Nf1 knockout: Inactivation of both Nf1 alleles in Sox10+ cells generates classic nodular cutaneous and plexiform neurofibromas that completely recapitulate human counterparts – described as the first genetically engineered mouse model of nodular cutaneous neurofibroma (mo2025humanizedneurofibromamodel pages 1-2)

Porcine Models

Genetically engineered NF1-mutant minipigs closely resemble human neurofibromas histologically and contain all known cellular components of their human counterparts, including Schwann cells, fibroblasts, immune cells, and vascular elements. These models are used for single-cell transcriptomic profiling and preclinical drug testing (mclean2023singlecellrnasequencing pages 16-17, mclean2023singlecellrnasequencing pages 1-2).

iPSC-Derived Models

Patient-specific NF1-mutant human induced pluripotent stem cells (hiPSCs) differentiated into Schwannian lineage cells (SLCs) form bona fide neurofibromas upon mouse sciatic nerve implantation when NF1-null, while wild-type and heterozygous cells do not (mo2025humanizedneurofibromamodel pages 1-2).

Model Limitations

Current tissue-specific knockout models primarily recapitulate para-spinal neurofibromas (a rare subtype in humans), and de novo rapid MPNST development in mice does not accurately mirror the slow human neurofibroma-to-MPNST progression (plante2024revisitingthenpcis pages 8-11, mclean2023singlecellrnasequencing pages 1-2).

13. Summary

Neurofibroma represents the defining neoplastic manifestation of NF1, driven by biallelic inactivation of the NF1 tumor suppressor gene and constitutive RAS/MAPK pathway activation. The disease has undergone a therapeutic revolution with the approval of MEK inhibitors, particularly selumetinib (68–71% partial response rate) and mirdametinib (42–50% partial response rate) for inoperable plexiform neurofibromas (souza2022clinicaltrialstargeting pages 5-6, armstrong2023treatmentdecisionsand pages 2-4). Single-cell transcriptomic studies have revealed the remarkable complexity of the neurofibroma tumor microenvironment, with immune and stromal cells comprising ~90% of tumor cellularity and multiple immunosuppressive mechanisms identified (kershner2022multiplenf1schwann pages 1-2, mclean2023singlecellrnasequencing pages 11-13, mclean2023singlecellrnasequencing pages 14-15). The malignant transformation pathway from neurofibroma to MPNST involves sequential loss of CDKN2A and PRC2 components, representing actionable biomarkers for early detection and therapeutic targeting (busciglio2025thepathogenesisof pages 2-4, busciglio2025thepathogenesisof pages 1-2). Ongoing clinical trials are exploring prevention strategies, topical MEK inhibitors for cutaneous neurofibromas, and gene therapy approaches, representing a rapidly evolving therapeutic landscape for this complex tumor predisposition syndrome.

References

  1. (sur2022neurofibromatosisinchildren pages 1-2): Maria Lucia Sur, Ionel Armat, Genel Sur, Diana-Cristina Pop, Gabriel Samasca, Iulia Lupan, Teodora-Larisa Timis, Ioan-Alexandru Florian, and Daniel Sur. Neurofibromatosis in children: actually and perspectives. Children, 9:40, Jan 2022. URL: https://doi.org/10.3390/children9010040, doi:10.3390/children9010040. This article has 19 citations.

  2. (mo2022neurofibrominandsuppression pages 1-3): Juan Mo, Stefanie L. Moye, Renee M. McKay, and Lu Q. Le. Neurofibromin and suppression of tumorigenesis: beyond the gap. Oncogene, 41:1235-1251, Jan 2022. URL: https://doi.org/10.1038/s41388-021-02156-y, doi:10.1038/s41388-021-02156-y. This article has 99 citations and is from a domain leading peer-reviewed journal.

  3. (kitsera2026moleculargeneticsand pages 2-3): N.I. Kitsera, M.I. Drobchak, M.V. Bondarenko, R.V. Kozovyi, L.Ye. Kovalchuk, O.I. Dorosh, and I.L. Kozova. Molecular genetics and clinical spectrum of neurofibromatosis type 1 in patients: a case-based review. CHILD`S HEALTH, 21:49-59, Mar 2026. URL: https://doi.org/10.22141/2224-0551.21.1.2026.1939, doi:10.22141/2224-0551.21.1.2026.1939. This article has 0 citations.

  4. (anastasaki2022rasandbeyond pages 2-3): Corina Anastasaki, Paola Orozco, and David H. Gutmann. Ras and beyond: the many faces of the neurofibromatosis type 1 protein. Disease Models & Mechanisms, Feb 2022. URL: https://doi.org/10.1242/dmm.049362, doi:10.1242/dmm.049362. This article has 108 citations and is from a domain leading peer-reviewed journal.

  5. (sur2022neurofibromatosisinchildren pages 2-4): Maria Lucia Sur, Ionel Armat, Genel Sur, Diana-Cristina Pop, Gabriel Samasca, Iulia Lupan, Teodora-Larisa Timis, Ioan-Alexandru Florian, and Daniel Sur. Neurofibromatosis in children: actually and perspectives. Children, 9:40, Jan 2022. URL: https://doi.org/10.3390/children9010040, doi:10.3390/children9010040. This article has 19 citations.

  6. (yu2025emergingmechanismand pages 2-4): Xuan Yu, Yi-Hui Gu, Jun Liu, Jing-Xuan Huang, Qingfeng Li, and Zhichao Wang. Emerging mechanism and therapeutic potential of neurofibromatosis type 1-related nerve system tumor: advancing insights into tumor development. Neuro-Oncology Advances, Feb 2025. URL: https://doi.org/10.1093/noajnl/vdaf040, doi:10.1093/noajnl/vdaf040. This article has 2 citations and is from a peer-reviewed journal.

  7. (imataka2025neurofibromatosistype1 pages 4-5): George Imataka, Shigeko Kuwashima, Shujiro Hayashi, Kei Ogino, Eisei Hoshiyama, Katsuhiko Naruse, and Hideaki Shiraishi. Neurofibromatosis type 1 and mek inhibition: a comprehensive review with focus on selumetinib therapy. Journal of Clinical Medicine, Jul 2025. URL: https://doi.org/10.3390/jcm14145071, doi:10.3390/jcm14145071. This article has 6 citations.

  8. (lee2023incidenceandprevalence pages 1-2): Tin-Suet Joan Lee, Meera Chopra, Raymond H. Kim, Patricia C. Parkin, and Carolina Barnett-Tapia. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet Journal of Rare Diseases, Sep 2023. URL: https://doi.org/10.1186/s13023-023-02911-2, doi:10.1186/s13023-023-02911-2. This article has 171 citations and is from a peer-reviewed journal.

  9. (lee2023incidenceandprevalence pages 2-4): Tin-Suet Joan Lee, Meera Chopra, Raymond H. Kim, Patricia C. Parkin, and Carolina Barnett-Tapia. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet Journal of Rare Diseases, Sep 2023. URL: https://doi.org/10.1186/s13023-023-02911-2, doi:10.1186/s13023-023-02911-2. This article has 171 citations and is from a peer-reviewed journal.

  10. (hussain2024roleoflong pages 3-5): Md Sadique Hussain, Somya Sharma, Alka Kumari, Almaz Kamran, Gurusha Bahl, Ajay Singh Bisht, Ayesha Sultana, Sumel Ashique, Prasanna Srinivasan Ramalingam, and Sivakumar Arumugam. Role of long non-coding rnas in neurofibromatosis and schwannomatosis: pathogenesis and therapeutic potential. Epigenomics, 16:1-12, Nov 2024. URL: https://doi.org/10.1080/17501911.2024.2430170, doi:10.1080/17501911.2024.2430170. This article has 15 citations and is from a peer-reviewed journal.

  11. (lu2025neurofibromatosistype1 pages 2-4): Yuqing Lu, Manzhu Xu, Xiaojun Chen, Huazhen Xu, Nihao Sun, Karis E. Weisgerber, and Ren-Yuan Bai. Neurofibromatosis type 1: genetic mechanisms and advances in therapeutic innovation. Cancers, 17:3788, Nov 2025. URL: https://doi.org/10.3390/cancers17233788, doi:10.3390/cancers17233788. This article has 3 citations.

  12. (OpenTargets Search: neurofibroma): Open Targets Query (neurofibroma, 42 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  13. (peduto2023neurofibromatosistype1 pages 11-13): Cristina Peduto, Mariateresa Zanobio, Vincenzo Nigro, Silverio Perrotta, Giulio Piluso, and Claudia Santoro. Neurofibromatosis type 1: pediatric aspects and review of genotype–phenotype correlations. Cancers, 15:1217, Feb 2023. URL: https://doi.org/10.3390/cancers15041217, doi:10.3390/cancers15041217. This article has 88 citations.

  14. (yao2023malignantperipheralnerve pages 2-4): Chengjun Yao, Haiying Zhou, Yanzhao Dong, Ahmad Alhaskawi, Sohaib Hasan Abdullah Ezzi, Zewei Wang, Jingtian Lai, Vishnu Goutham Kota, Mohamed Hasan Abdulla Hasan Abdulla, and Hui Lu. Malignant peripheral nerve sheath tumors: latest concepts in disease pathogenesis and clinical management. Cancers, 15:1077, Feb 2023. URL: https://doi.org/10.3390/cancers15041077, doi:10.3390/cancers15041077. This article has 129 citations.

  15. (plante2024revisitingthenpcis pages 8-11): Camille Plante, Teddy Mohamad, Dhanushka Hewa Bostanthirige, Michel Renaud, Harsimran Sidhu, Michel ElChoueiry, Jean-Paul Sabo Vatasescu, Mikael Poirier, Sameh Geha, and Jean-Philippe Brosseau. Revisiting the npcis mouse model: a new tool to model plexiform neurofibroma. PLOS ONE, 19:e0301040, Jun 2024. URL: https://doi.org/10.1371/journal.pone.0301040, doi:10.1371/journal.pone.0301040. This article has 1 citations and is from a peer-reviewed journal.

  16. (plante2024revisitingthenpcis pages 1-2): Camille Plante, Teddy Mohamad, Dhanushka Hewa Bostanthirige, Michel Renaud, Harsimran Sidhu, Michel ElChoueiry, Jean-Paul Sabo Vatasescu, Mikael Poirier, Sameh Geha, and Jean-Philippe Brosseau. Revisiting the npcis mouse model: a new tool to model plexiform neurofibroma. PLOS ONE, 19:e0301040, Jun 2024. URL: https://doi.org/10.1371/journal.pone.0301040, doi:10.1371/journal.pone.0301040. This article has 1 citations and is from a peer-reviewed journal.

  17. (lalvani2024neurofibromatosistype1 pages 1-2): Shaan Lalvani and Rebecca Brown. Neurofibromatosis type 1: optimizing management with a multidisciplinary approach. Journal of Multidisciplinary Healthcare, 17:1803-1817, Apr 2024. URL: https://doi.org/10.2147/jmdh.s362791, doi:10.2147/jmdh.s362791. This article has 31 citations and is from a peer-reviewed journal.

  18. (imataka2025neurofibromatosistype1 pages 2-4): George Imataka, Shigeko Kuwashima, Shujiro Hayashi, Kei Ogino, Eisei Hoshiyama, Katsuhiko Naruse, and Hideaki Shiraishi. Neurofibromatosis type 1 and mek inhibition: a comprehensive review with focus on selumetinib therapy. Journal of Clinical Medicine, Jul 2025. URL: https://doi.org/10.3390/jcm14145071, doi:10.3390/jcm14145071. This article has 6 citations.

  19. (almuqbil2024epidemiologyandoutcomes pages 1-2): Mohammed Almuqbil, Fatimah Alshaikh, Waleed Altwaijri, Duaa Baarmah, Raid Hommady, Maryam Alshaikh, Fares Alammari, Meshal Alhussain, Reem Almotawa, Faris Alqarni, Amna Kashgari, Rayan Alkhodair, Jumanah Alkhater, Lujeen Alkhater, Sawsan Alharthi, Mada Alsadi, and Ahmed AlRumayyan. Epidemiology and outcomes of neurofibromatosis type 1 (nf-1): multicenter tertiary experience. Journal of Multidisciplinary Healthcare, 17:1303-1314, Mar 2024. URL: https://doi.org/10.2147/jmdh.s454921, doi:10.2147/jmdh.s454921. This article has 14 citations and is from a peer-reviewed journal.

  20. (almuqbil2024epidemiologyandoutcomes pages 5-7): Mohammed Almuqbil, Fatimah Alshaikh, Waleed Altwaijri, Duaa Baarmah, Raid Hommady, Maryam Alshaikh, Fares Alammari, Meshal Alhussain, Reem Almotawa, Faris Alqarni, Amna Kashgari, Rayan Alkhodair, Jumanah Alkhater, Lujeen Alkhater, Sawsan Alharthi, Mada Alsadi, and Ahmed AlRumayyan. Epidemiology and outcomes of neurofibromatosis type 1 (nf-1): multicenter tertiary experience. Journal of Multidisciplinary Healthcare, 17:1303-1314, Mar 2024. URL: https://doi.org/10.2147/jmdh.s454921, doi:10.2147/jmdh.s454921. This article has 14 citations and is from a peer-reviewed journal.

  21. (peduto2023neurofibromatosistype1 pages 2-4): Cristina Peduto, Mariateresa Zanobio, Vincenzo Nigro, Silverio Perrotta, Giulio Piluso, and Claudia Santoro. Neurofibromatosis type 1: pediatric aspects and review of genotype–phenotype correlations. Cancers, 15:1217, Feb 2023. URL: https://doi.org/10.3390/cancers15041217, doi:10.3390/cancers15041217. This article has 88 citations.

  22. (busciglio2025thepathogenesisof pages 1-2): Sabrina Busciglio, Ilenia Rita Cannizzaro, Anita Luberto, Antonietta Taiani, Barbara Moschella, Enrico Ambrosini, Sofia Cesarini, Mirko Treccani, Cinzia Azzoni, Lorena Bottarelli, Domenico Corradi, Vera Uliana, Davide Martorana, Valeria Barili, and Antonio Percesepe. The pathogenesis of the neurofibroma-to-sarcoma transition in neurofibromatosis type i: from molecular profiles to diagnostic applications. Cancers, 17:3955, Dec 2025. URL: https://doi.org/10.3390/cancers17243955, doi:10.3390/cancers17243955. This article has 3 citations.

  23. (almuqbil2024epidemiologyandoutcomes pages 2-4): Mohammed Almuqbil, Fatimah Alshaikh, Waleed Altwaijri, Duaa Baarmah, Raid Hommady, Maryam Alshaikh, Fares Alammari, Meshal Alhussain, Reem Almotawa, Faris Alqarni, Amna Kashgari, Rayan Alkhodair, Jumanah Alkhater, Lujeen Alkhater, Sawsan Alharthi, Mada Alsadi, and Ahmed AlRumayyan. Epidemiology and outcomes of neurofibromatosis type 1 (nf-1): multicenter tertiary experience. Journal of Multidisciplinary Healthcare, 17:1303-1314, Mar 2024. URL: https://doi.org/10.2147/jmdh.s454921, doi:10.2147/jmdh.s454921. This article has 14 citations and is from a peer-reviewed journal.

  24. (liang2024longtermdistressthroughout pages 1-2): Wanxian Liang, Shihuan Cao, Yusi Suo, Lining Zhang, Lujia Yang, Ping Wang, Hanfei Wang, Hanfei Wang, Guannan Bai, Qingnan Li, Jiayin Zheng, and Xuejing Jin. Long-term distress throughout one’s life: health-related quality of life, economic and caregiver burden of patients with neurofibromatosis type 1 in china. Frontiers in Public Health, Aug 2024. URL: https://doi.org/10.3389/fpubh.2024.1398803, doi:10.3389/fpubh.2024.1398803. This article has 4 citations.

  25. (liang2024longtermdistressthroughout pages 4-5): Wanxian Liang, Shihuan Cao, Yusi Suo, Lining Zhang, Lujia Yang, Ping Wang, Hanfei Wang, Hanfei Wang, Guannan Bai, Qingnan Li, Jiayin Zheng, and Xuejing Jin. Long-term distress throughout one’s life: health-related quality of life, economic and caregiver burden of patients with neurofibromatosis type 1 in china. Frontiers in Public Health, Aug 2024. URL: https://doi.org/10.3389/fpubh.2024.1398803, doi:10.3389/fpubh.2024.1398803. This article has 4 citations.

  26. (mo2022neurofibrominandsuppression pages 19-21): Juan Mo, Stefanie L. Moye, Renee M. McKay, and Lu Q. Le. Neurofibromin and suppression of tumorigenesis: beyond the gap. Oncogene, 41:1235-1251, Jan 2022. URL: https://doi.org/10.1038/s41388-021-02156-y, doi:10.1038/s41388-021-02156-y. This article has 99 citations and is from a domain leading peer-reviewed journal.

  27. (busciglio2025thepathogenesisof pages 2-4): Sabrina Busciglio, Ilenia Rita Cannizzaro, Anita Luberto, Antonietta Taiani, Barbara Moschella, Enrico Ambrosini, Sofia Cesarini, Mirko Treccani, Cinzia Azzoni, Lorena Bottarelli, Domenico Corradi, Vera Uliana, Davide Martorana, Valeria Barili, and Antonio Percesepe. The pathogenesis of the neurofibroma-to-sarcoma transition in neurofibromatosis type i: from molecular profiles to diagnostic applications. Cancers, 17:3955, Dec 2025. URL: https://doi.org/10.3390/cancers17243955, doi:10.3390/cancers17243955. This article has 3 citations.

  28. (busciglio2025thepathogenesisof pages 4-6): Sabrina Busciglio, Ilenia Rita Cannizzaro, Anita Luberto, Antonietta Taiani, Barbara Moschella, Enrico Ambrosini, Sofia Cesarini, Mirko Treccani, Cinzia Azzoni, Lorena Bottarelli, Domenico Corradi, Vera Uliana, Davide Martorana, Valeria Barili, and Antonio Percesepe. The pathogenesis of the neurofibroma-to-sarcoma transition in neurofibromatosis type i: from molecular profiles to diagnostic applications. Cancers, 17:3955, Dec 2025. URL: https://doi.org/10.3390/cancers17243955, doi:10.3390/cancers17243955. This article has 3 citations.

  29. (busciglio2025thepathogenesisof pages 6-7): Sabrina Busciglio, Ilenia Rita Cannizzaro, Anita Luberto, Antonietta Taiani, Barbara Moschella, Enrico Ambrosini, Sofia Cesarini, Mirko Treccani, Cinzia Azzoni, Lorena Bottarelli, Domenico Corradi, Vera Uliana, Davide Martorana, Valeria Barili, and Antonio Percesepe. The pathogenesis of the neurofibroma-to-sarcoma transition in neurofibromatosis type i: from molecular profiles to diagnostic applications. Cancers, 17:3955, Dec 2025. URL: https://doi.org/10.3390/cancers17243955, doi:10.3390/cancers17243955. This article has 3 citations.

  30. (busciglio2025thepathogenesisof pages 14-14): Sabrina Busciglio, Ilenia Rita Cannizzaro, Anita Luberto, Antonietta Taiani, Barbara Moschella, Enrico Ambrosini, Sofia Cesarini, Mirko Treccani, Cinzia Azzoni, Lorena Bottarelli, Domenico Corradi, Vera Uliana, Davide Martorana, Valeria Barili, and Antonio Percesepe. The pathogenesis of the neurofibroma-to-sarcoma transition in neurofibromatosis type i: from molecular profiles to diagnostic applications. Cancers, 17:3955, Dec 2025. URL: https://doi.org/10.3390/cancers17243955, doi:10.3390/cancers17243955. This article has 3 citations.

  31. (busciglio2025thepathogenesisof pages 10-12): Sabrina Busciglio, Ilenia Rita Cannizzaro, Anita Luberto, Antonietta Taiani, Barbara Moschella, Enrico Ambrosini, Sofia Cesarini, Mirko Treccani, Cinzia Azzoni, Lorena Bottarelli, Domenico Corradi, Vera Uliana, Davide Martorana, Valeria Barili, and Antonio Percesepe. The pathogenesis of the neurofibroma-to-sarcoma transition in neurofibromatosis type i: from molecular profiles to diagnostic applications. Cancers, 17:3955, Dec 2025. URL: https://doi.org/10.3390/cancers17243955, doi:10.3390/cancers17243955. This article has 3 citations.

  32. (mo2025humanizedneurofibromamodel pages 1-2): Juan Mo, Corina Anastasaki, Zhiguo Chen, Tracey Shipman, Jason Papke, Kevin Yin, David H. Gutmann, and Lu Q. Le. Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins. Journal of Clinical Investigation, Jan 2025. URL: https://doi.org/10.1172/jci139807, doi:10.1172/jci139807. This article has 81 citations and is from a highest quality peer-reviewed journal.

  33. (kershner2022multiplenf1schwann pages 1-2): Leah J. Kershner, Kwangmin Choi, Jianqiang Wu, Xiyuan Zhang, Melissa Perrino, Nathan Salomonis, Jack F. Shern, and Nancy Ratner. Multiple nf1 schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment. JCI Insight, Sep 2022. URL: https://doi.org/10.1172/jci.insight.154513, doi:10.1172/jci.insight.154513. This article has 60 citations and is from a domain leading peer-reviewed journal.

  34. (mclean2023singlecellrnasequencing pages 5-6): Dalton T. McLean, J. Meudt, Loren D. Lopez Rivera, Dominic T. Schomberg, Derek M Pavelec, Tyler T. Duellman, Darya G. Buehler, Patrick B. Schwartz, Melissa Graham, Laura M. Lee, Keri D. Graff, Jamie L Reichert, Sandra S. Bon-Durant, Charles M. Konsitzke, Sean M. Ronnekleiv-Kelly, D. Shanmuganayagam, C. Rubinstein, Luciane R. Cavalli, Zhirui Zeng, and Paula Dobosz. Single-cell rna sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model. Frontiers in Oncology, Sep 2023. URL: https://doi.org/10.3389/fonc.2023.1253659, doi:10.3389/fonc.2023.1253659. This article has 5 citations.

  35. (mclean2023singlecellrnasequencing pages 11-13): Dalton T. McLean, J. Meudt, Loren D. Lopez Rivera, Dominic T. Schomberg, Derek M Pavelec, Tyler T. Duellman, Darya G. Buehler, Patrick B. Schwartz, Melissa Graham, Laura M. Lee, Keri D. Graff, Jamie L Reichert, Sandra S. Bon-Durant, Charles M. Konsitzke, Sean M. Ronnekleiv-Kelly, D. Shanmuganayagam, C. Rubinstein, Luciane R. Cavalli, Zhirui Zeng, and Paula Dobosz. Single-cell rna sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model. Frontiers in Oncology, Sep 2023. URL: https://doi.org/10.3389/fonc.2023.1253659, doi:10.3389/fonc.2023.1253659. This article has 5 citations.

  36. (mclean2023singlecellrnasequencing pages 14-15): Dalton T. McLean, J. Meudt, Loren D. Lopez Rivera, Dominic T. Schomberg, Derek M Pavelec, Tyler T. Duellman, Darya G. Buehler, Patrick B. Schwartz, Melissa Graham, Laura M. Lee, Keri D. Graff, Jamie L Reichert, Sandra S. Bon-Durant, Charles M. Konsitzke, Sean M. Ronnekleiv-Kelly, D. Shanmuganayagam, C. Rubinstein, Luciane R. Cavalli, Zhirui Zeng, and Paula Dobosz. Single-cell rna sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model. Frontiers in Oncology, Sep 2023. URL: https://doi.org/10.3389/fonc.2023.1253659, doi:10.3389/fonc.2023.1253659. This article has 5 citations.

  37. (swanson2025singlecellanalysisof pages 12-15): Grace M Swanson, Marcia Arenas-Hernandez, and Katherine Gurdziel. Single-cell analysis of nf1 -expressing and nf1 -deficient schwann and fibroblast cells reveals divergent neurofibroma programs. BioRxiv, Sep 2025. URL: https://doi.org/10.1101/2025.09.26.677858, doi:10.1101/2025.09.26.677858. This article has 0 citations.

  38. (swanson2025singlecellanalysisof pages 25-27): Grace M Swanson, Marcia Arenas-Hernandez, and Katherine Gurdziel. Single-cell analysis of nf1 -expressing and nf1 -deficient schwann and fibroblast cells reveals divergent neurofibroma programs. BioRxiv, Sep 2025. URL: https://doi.org/10.1101/2025.09.26.677858, doi:10.1101/2025.09.26.677858. This article has 0 citations.

  39. (lee2023incidenceandprevalence pages 4-7): Tin-Suet Joan Lee, Meera Chopra, Raymond H. Kim, Patricia C. Parkin, and Carolina Barnett-Tapia. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet Journal of Rare Diseases, Sep 2023. URL: https://doi.org/10.1186/s13023-023-02911-2, doi:10.1186/s13023-023-02911-2. This article has 171 citations and is from a peer-reviewed journal.

  40. (armstrong2023treatmentdecisionsand pages 2-4): Amy E. Armstrong, Allan J. Belzberg, John R. Crawford, Angela C. Hirbe, and Zhihong J. Wang. Treatment decisions and the use of mek inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas. BMC Cancer, Jun 2023. URL: https://doi.org/10.1186/s12885-023-10996-y, doi:10.1186/s12885-023-10996-y. This article has 97 citations and is from a peer-reviewed journal.

  41. (souza2022clinicaltrialstargeting pages 5-6): Gabriel Roman Souza, Ahmed Abdalla, and Daruka Mahadevan. Clinical trials targeting neurofibromatoses-associated tumors: a systematic review. Neuro-oncology Advances, Jan 2022. URL: https://doi.org/10.1093/noajnl/vdac005, doi:10.1093/noajnl/vdac005. This article has 18 citations and is from a peer-reviewed journal.

  42. (souza2022clinicaltrialstargeting pages 9-10): Gabriel Roman Souza, Ahmed Abdalla, and Daruka Mahadevan. Clinical trials targeting neurofibromatoses-associated tumors: a systematic review. Neuro-oncology Advances, Jan 2022. URL: https://doi.org/10.1093/noajnl/vdac005, doi:10.1093/noajnl/vdac005. This article has 18 citations and is from a peer-reviewed journal.

  43. (imataka2025neurofibromatosistype1 pages 9-11): George Imataka, Shigeko Kuwashima, Shujiro Hayashi, Kei Ogino, Eisei Hoshiyama, Katsuhiko Naruse, and Hideaki Shiraishi. Neurofibromatosis type 1 and mek inhibition: a comprehensive review with focus on selumetinib therapy. Journal of Clinical Medicine, Jul 2025. URL: https://doi.org/10.3390/jcm14145071, doi:10.3390/jcm14145071. This article has 6 citations.

  44. (imataka2025neurofibromatosistype1 pages 12-13): George Imataka, Shigeko Kuwashima, Shujiro Hayashi, Kei Ogino, Eisei Hoshiyama, Katsuhiko Naruse, and Hideaki Shiraishi. Neurofibromatosis type 1 and mek inhibition: a comprehensive review with focus on selumetinib therapy. Journal of Clinical Medicine, Jul 2025. URL: https://doi.org/10.3390/jcm14145071, doi:10.3390/jcm14145071. This article has 6 citations.

  45. (armstrong2023treatmentdecisionsand pages 6-7): Amy E. Armstrong, Allan J. Belzberg, John R. Crawford, Angela C. Hirbe, and Zhihong J. Wang. Treatment decisions and the use of mek inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas. BMC Cancer, Jun 2023. URL: https://doi.org/10.1186/s12885-023-10996-y, doi:10.1186/s12885-023-10996-y. This article has 97 citations and is from a peer-reviewed journal.

  46. (souza2022clinicaltrialstargeting pages 6-7): Gabriel Roman Souza, Ahmed Abdalla, and Daruka Mahadevan. Clinical trials targeting neurofibromatoses-associated tumors: a systematic review. Neuro-oncology Advances, Jan 2022. URL: https://doi.org/10.1093/noajnl/vdac005, doi:10.1093/noajnl/vdac005. This article has 18 citations and is from a peer-reviewed journal.

  47. (imataka2025neurofibromatosistype1 pages 7-9): George Imataka, Shigeko Kuwashima, Shujiro Hayashi, Kei Ogino, Eisei Hoshiyama, Katsuhiko Naruse, and Hideaki Shiraishi. Neurofibromatosis type 1 and mek inhibition: a comprehensive review with focus on selumetinib therapy. Journal of Clinical Medicine, Jul 2025. URL: https://doi.org/10.3390/jcm14145071, doi:10.3390/jcm14145071. This article has 6 citations.

  48. (plante2024revisitingthenpcis pages 11-12): Camille Plante, Teddy Mohamad, Dhanushka Hewa Bostanthirige, Michel Renaud, Harsimran Sidhu, Michel ElChoueiry, Jean-Paul Sabo Vatasescu, Mikael Poirier, Sameh Geha, and Jean-Philippe Brosseau. Revisiting the npcis mouse model: a new tool to model plexiform neurofibroma. PLOS ONE, 19:e0301040, Jun 2024. URL: https://doi.org/10.1371/journal.pone.0301040, doi:10.1371/journal.pone.0301040. This article has 1 citations and is from a peer-reviewed journal.

  49. (plante2024revisitingthenpcis pages 2-4): Camille Plante, Teddy Mohamad, Dhanushka Hewa Bostanthirige, Michel Renaud, Harsimran Sidhu, Michel ElChoueiry, Jean-Paul Sabo Vatasescu, Mikael Poirier, Sameh Geha, and Jean-Philippe Brosseau. Revisiting the npcis mouse model: a new tool to model plexiform neurofibroma. PLOS ONE, 19:e0301040, Jun 2024. URL: https://doi.org/10.1371/journal.pone.0301040, doi:10.1371/journal.pone.0301040. This article has 1 citations and is from a peer-reviewed journal.

  50. (mclean2023singlecellrnasequencing pages 16-17): Dalton T. McLean, J. Meudt, Loren D. Lopez Rivera, Dominic T. Schomberg, Derek M Pavelec, Tyler T. Duellman, Darya G. Buehler, Patrick B. Schwartz, Melissa Graham, Laura M. Lee, Keri D. Graff, Jamie L Reichert, Sandra S. Bon-Durant, Charles M. Konsitzke, Sean M. Ronnekleiv-Kelly, D. Shanmuganayagam, C. Rubinstein, Luciane R. Cavalli, Zhirui Zeng, and Paula Dobosz. Single-cell rna sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model. Frontiers in Oncology, Sep 2023. URL: https://doi.org/10.3389/fonc.2023.1253659, doi:10.3389/fonc.2023.1253659. This article has 5 citations.

  51. (mclean2023singlecellrnasequencing pages 1-2): Dalton T. McLean, J. Meudt, Loren D. Lopez Rivera, Dominic T. Schomberg, Derek M Pavelec, Tyler T. Duellman, Darya G. Buehler, Patrick B. Schwartz, Melissa Graham, Laura M. Lee, Keri D. Graff, Jamie L Reichert, Sandra S. Bon-Durant, Charles M. Konsitzke, Sean M. Ronnekleiv-Kelly, D. Shanmuganayagam, C. Rubinstein, Luciane R. Cavalli, Zhirui Zeng, and Paula Dobosz. Single-cell rna sequencing of neurofibromas reveals a tumor microenvironment favorable for neural regeneration and immune suppression in a neurofibromatosis type 1 porcine model. Frontiers in Oncology, Sep 2023. URL: https://doi.org/10.3389/fonc.2023.1253659, doi:10.3389/fonc.2023.1253659. This article has 5 citations.

Artifacts